WWhen pandemic lockdowns closed the doors of the community in March 2020, leaders at the Obsessive Compulsive Disorder Institute at McLean Hospital in Massachusetts needed a new plan. Some of the care they carefully provided is not personally safe anymore. By the end of April, McClain had overhauled her approach, launching online services for people who needed partial hospitalization.
Three thousand miles away, a similar trial was conducted on the same schedule at UCLA’s Intensive Obsessive-Compulsive Disorder Program, where patients came for more specialized help when light-touch treatments didn’t work. Moving software by default was a risky idea, but it came out of necessity. Intensive outpatient mental health care has, for years, relied on important steps designed for personal interactions: getting up and going to the outpatient program every day to create a sense of routine, coping skills through exposure therapy in real-world environments and participating in group sessions.
Open this article by subscribing to STAT+ and enjoy your first 30 days for free!
start
What is that?
STAT+ is STAT’s premium subscription service for in-depth coverage of biotechnology, pharmaceuticals, politics, life sciences and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific discoveries and clinical trial results, and the disruption of healthcare in Silicon Valley and beyond.
What does it contain?
- Daily reports and analysis
- The most comprehensive industry coverage from a strong team of reporters
- Newsletter for subscribers only
- Daily newsletters to keep you informed of the most important industry news today
- STAT + conversations
- Weekly opportunities to connect with our leading reporters and industry experts on live video chats
- EXCLUSIVE INDUSTRY EVENTS
- Excellent access to subscriber-only networking events across the country
- The best reporters in the industry
- The most trusted and connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like CRISPR Trackr.